Sustainable Development Report

Overview

The report presents Imexpharm's 2022 sustainable development performance, including total revenue of 1,668.2 billion VND, expansion to 11 EU-standard production lines, and employee and community programs. It organizes disclosures around GRI economic, environmental, and social topics and references the 17 UN Sustainable Development Goals. Operational environmental data are scoped to IMP1-IMP3, with IMP4 explicitly excluded because it began commercial operations in 2022.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services